Albireo Pharma Inc (ALBO) - Financial and Strategic SWOT Analysis Review

Albireo Pharma Inc (ALBO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Albireo Pharma Inc (Albireo), formerly Biodel Inc, focuses on the development and commercialization of novel bile acid modulators for treatment of orphan pediatric liver diseases, gastrointestinal (GI) disorders and other diseases. Its pipeline products include odevixibat (A4250) intended for treatment of progressive familial intrahepatic cholestasis (PFIC), biliary atresia, alagille syndrome and other cholestaticc; A3384 for bile acid malabsorption; and elobixibat for nonalcoholic steatohepatitis (NASH). Elobixibat is approved in Japan for the treatment of chronic constipation. The company is investigating bile acid modulator for nonalcoholic steatohepatitis (NASH) and other preclinical trials for the treatment of adult liver diseases. It operates in the US, the UK and Sweden. Albireo is headquartered in Boston, Massachusetts, the US.

Albireo Pharma Inc Key Recent Developments

May 07,2020: Albireo reports Q1 2020 financial results and provides business update
Mar 02,2020: Albireo reports fourth quarter and year-end 2019 financial results, and provides business update
Jan 23,2020: Albireo joins with Alagille Syndrome Community in celebrating First International Awareness Day
Nov 06,2019: Albireo reports third quarter 2019 financial results and provides business update
Nov 04,2019: Albireo appoints Michelle Graham as Chief Human Resources Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
 



Section 1 - About the Company
Albireo Pharma Inc - Key Facts
Albireo Pharma Inc - Key Employees
Albireo Pharma Inc - Key Employee Biographies
Albireo Pharma Inc - Major Products and Services
Albireo Pharma Inc - History
Albireo Pharma Inc - Company Statement
Albireo Pharma Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Albireo Pharma Inc - Business Description
R&D Overview
Albireo Pharma Inc - Corporate Strategy
Albireo Pharma Inc - SWOT Analysis
SWOT Analysis - Overview
Albireo Pharma Inc - Strengths
Albireo Pharma Inc - Weaknesses
Albireo Pharma Inc - Opportunities
Albireo Pharma Inc - Threats
Albireo Pharma Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Albireo Pharma Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
May 07, 2020: Albireo reports Q1 2020 financial results and provides business update
Mar 02, 2020: Albireo reports fourth quarter and year-end 2019 financial results, and provides business update
Jan 23, 2020: Albireo joins with Alagille Syndrome Community in celebrating First International Awareness Day
Nov 06, 2019: Albireo reports third quarter 2019 financial results and provides business update
Nov 04, 2019: Albireo appoints Michelle Graham as Chief Human Resources Officer
Aug 08, 2019: Albireo reports second quarter 2019 financial results
May 09, 2019: Albireo reports first quarter 2019 financial results
Mar 21, 2019: Albireo expands executive leadership team with appointment of Pamela Stephenson as Chief Commercial Officer
Mar 07, 2019: Albireo reports year-end 2018 financial results and provides pipeline update
Feb 28, 2019: Albireo recognizes rare disease day and highlights urgent need to support families affected by progressive familial intrahepatic cholestasis (pfic)
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
 


List Of Tables

 
Albireo Pharma Inc, Key Facts
Albireo Pharma Inc, Key Employees
Albireo Pharma Inc, Key Employee Biographies
Albireo Pharma Inc, Major Products and Services
Albireo Pharma Inc, History
Albireo Pharma Inc, Subsidiaries
Albireo Pharma Inc, Key Competitors
Albireo Pharma Inc, Ratios based on current share price
Albireo Pharma Inc, Annual Ratios
Albireo Pharma Inc, Annual Ratios (Cont...1)
Albireo Pharma Inc, Interim Ratios
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Albireo Pharma Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
 


List Of Figures

 
Albireo Pharma Inc, Performance Chart (2015 - 2019)
Albireo Pharma Inc, Ratio Charts
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020
 


Albireo Pharma Inc (ALBO) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Albireo Pharma Inc (Albireo), formerly Biodel Inc., focuses on the development and commercialization of innovative bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal (GI)

USD 250 View Report

Albireo Pharma Inc (ALBO) - Medical Equipment - Deals and Alliances Profile

Albireo Pharma Inc (Albireo), formerly Biodel Inc., focuses on the development and commercialization of innovative bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal (GI)

USD 250 View Report

Benitec Biopharma Inc (BNTC) - Financial and Strategic SWOT Analysis Review

Benitec Biopharma Inc (BNTC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to

USD 125 View Report

Lumos Pharma Inc (LUMO) - Financial and Strategic SWOT Analysis Review

Lumos Pharma Inc (LUMO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to

USD 125 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available